Read More Pharma Industry News UCB’s BIMZELX shows sustained inflammation control at three years in psoriatic arthritis and axial spondyloarthritis Discover how UCB’s BIMZELX three-year data show lasting inflammation control in PsA and axSpA—find out what’s next for the treatment landscape. bySrinathOctober 25, 2025